Literature DB >> 7691241

Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium.

R A Swerlick1, J R Eckman, A Kumar, M Jeitler, T M Wick.   

Abstract

Important complications in sickle cell anemia occur secondary to vascular occlusion, which is postulated to be initiated by interactions of erythrocytes with vascular endothelial cells. In patients with sickle cell anemia, up to 25% of reticulocytes express the alpha 4 beta 1-integrin complex. Furthermore, erythrocytes from patients with sickle cell anemia bind to endothelial cells activated by tumor necrosis factor alpha via (TNF alpha) via interactions between erythrocyte alpha 4 beta 1 and endothelial cell vascular cell adhesion molecule-1 (VCAM-1). Thus, binding of alpha 4 beta 1-expressing reticulocytes to cytokine-activated endothelial cells may initiate vascular complications in sickle cell anemia and perhaps other hemolytic anemias during episodes of infection and inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691241

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors:  Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice.

Authors:  D K Kaul; R P Hebbel
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 3.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

4.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

Review 5.  Sickle cell disease: old discoveries, new concepts, and future promise.

Authors:  Paul S Frenette; George F Atweh
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 6.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

7.  The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.

Authors:  R Alon; P D Kassner; M W Carr; E B Finger; M E Hemler; T A Springer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

8.  An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.

Authors:  G D Turner; H Morrison; M Jones; T M Davis; S Looareesuwan; I D Buley; K C Gatter; C I Newbold; S Pukritayakamee; B Nagachinta
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.

Authors:  Marie-Marcelle Trinh-Trang-Tan; Camilo Vilela-Lamego; Julien Picot; Marie-Paule Wautier; Jean-Pierre Cartron
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

Authors:  Robert P Hebbel; Gregory M Vercellotti; Betty S Pace; Anna N Solovey; Rahn Kollander; Chine F Abanonu; Julia Nguyen; Julie V Vineyard; John D Belcher; Fuad Abdulla; Shadé Osifuye; John W Eaton; Robert J Kelm; Arne Slungaard
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.